Nearly One in Five American Adults Who Have Had COVID-19 Still Have "Long COVID"
Source : https://www.cdc.gov/nchs/pressroom/nchs_press_releases/2022/20220622.htm
New data from the Household Pulse Survey show that more than 40% of adults in the United States reported having COVID-19 in the past, and nearly one in five of...
For all U.S. adults, the new data show:
Overall, 1 in 13 adults in the U.S. (7.5%) have “long COVID” symptoms, defined as symptoms lasting three or more months after first contracting the virus, and that they didn’t have prior to their COVID-19 infection.
Older adults are less likely to have long COVID than younger adults. Nearly three...
Nitric oxide boosts oxygen in pregnant women with COVID-19 pneumonia
Inhaled high-dose nitric oxide (INO 200) safely shortened time on supplemental oxygen and hospital stays among pregnant women diagnosed as having severe bilateral COVID-19 pneumonia, suggests a new study led...
"Being able to wean patients from respiratory support quicker could have other profound implications, including reducing stress on women and their families, lowering the risk of hospital-acquired infections, and relieving the burden on the health care system," Berra said. "We hope more physicians will consider incorporating it into carefully...
Abatacept, Infliximab Improved Survival in Adults Hospitalized With COVID-19
Topline results were announced from a phase 3 trial evaluating the efficacy and safety of a single dose of abatacept or infliximab in adults hospitalized with moderate to severe COVID-19....
-
Focus on Infectious Disease4yrThe Phase 3 NIH study assessed the efficacy and safety of a single dose of immune modulators including intravenous abatacept (Orencia) 10 mg/kg compared with placebo and standard of care Show More
Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19
Source : https://www.nejm.org/doi/full/10.1056/NEJMoa2116620
The monoclonal-antibody combination AZD7442 is composed of tixagevimab and cilgavimab, two neutralizing antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that have an extended half-life and have been shown...
Conclusions: A single dose of AZD7442 had efficacy for the prevention of Covid-19, without evident safety concerns. (Funded by AstraZeneca and the U.S. government; PROVENT ClinicalTrials.gov number, NCT04625725. opens in new tab.)
Post-Acute Sequelae of SARS-CoV-2 Infection: A Descriptive Clinical Study
Source : https://neuro.psychiatryonline.org/doi/10.1176/appi.neuropsych.21070193
The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in...
Conclusions: These preliminary findings suggest that post-acute sequelae of SARS-CoV-2 vary in frequency and duration with relation to premorbid history and that these conditions affect functional domains and patients’ ability to return to work. Longitudinal research with larger cohorts is needed to characterize PASC and to optimize care,...